Corvus Pharmaceuticals Q3 2026: R&D Surge Widens Loss as Soquelitinib Pipeline Expands
As seen on the 24/7 Wall St. homepage on November 5, 2026.
R&D spending more than doubled to $17.8 million as Corvus pushes soquelitinib into lymphoma, eczema, hidradenitis suppurativa and now asthma, widening the loss past consensus. The $202.9 million cash pile funds operations into the second quarter of 2028, which covers the 2027 readouts that decide this story.
Continue ReadingShow less
Corvus Pharmaceuticals reported a third-quarter 2026 GAAP loss of $0.22 per share, missing expectations. The wider loss was the direct result of a near-doubling of research and development expenses, which climbed to $17.8 million on higher clinical trial costs for soquelitinib and increased headcount.
The spending acceleration reflects how aggressively Corvus is broadening the soquelitinib program. The ITK inhibitor is now being pursued across relapsed/refractory peripheral T-cell lymphoma in a registrational Phase 3 trial, atopic dermatitis in a Phase 2 randomized trial, hidradenitis suppurativa in a Phase 1b study, and an asthma trial targeting both T2 and non-T2 patients that management expects to initiate by Q1 2027. The asthma program moves soquelitinib into a large and largely unsolved therapeutic area.
Chief executive Richard A. Miller highlighted the breadth of the pipeline in prepared remarks, noting that the Phase 3 peripheral T-cell lymphoma and Phase 2 atopic dermatitis trials are on track and that there has been strong interest in the new hidradenitis suppurativa trial. He added that soquelitinib's mechanism affecting Th2, Th17 and T regulatory cells underpins its potential in both types of asthma patients, with the hidradenitis suppurativa trial expected to generate data that informs that hypothesis.
Sponsored
The results also included a non-cash loss of $0.9 million from Corvus's equity-method investment in Angel Pharmaceuticals, which is running its own soquelitinib trials in China. Angel completed enrollment of cohort 1 of a Phase 1b/2 atopic dermatitis study, with topline data anticipated in March 2027, and has a separate asthma Phase 2 planned for Q2 2027.
The company ended the quarter with $202.9 million in cash, cash equivalents and marketable securities, a position bolstered by approximately $189.4 million in net proceeds from a financing closed in January 2026. Management stated that runway extends into the second quarter of 2028, which is designed to carry the company through the cluster of soquelitinib data readouts expected across 2027. Those results, particularly from the Phase 3 lymphoma trial and the atopic dermatitis studies, will be the primary determinants of where this story goes next.
One additional milestone on the near-term calendar is a presentation of ALPS Phase 2 data at the ASH Annual Meeting in December 2026, covering a trial run with the NIAID in which all three treated patients responded over 360 days with no grade 3 or 4 adverse events. The company is also planning an FDA meeting to expand that program to more treatment centers and to include pediatric patients.
Mentioned: CRVS